Incyte Corporation (INCY) recently presented positive results on its oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB024360, at the annual meeting of American Society of Clinical Oncology (TATD).
Incyte enrolled 52 patients suffering from advanced malignancies for the open-label, single-agent, dose-escalation phase I study. Results from the study revealed that IDO1 inhibition was found in patients who were treated with INCB024360. Moreover, IDO1 activity was more than 90% when patients were treated with multiple doses of the compound. All the doses were well tolerated during the study.
The company stated that INCB024360 can be effective as a monotherapy. However, Incyte believes that it can be more beneficial in combination with other cancer agents.
Fatigue, gastrointestinal disturbances, abdominal pain and hypokalemia were some of the most common adverse events observed during the study.
Currently, Incyte is evaluating INCB024360 in a randomized phase I/II study in combination with Bristol-Myers Squibb Company’s (BMY) Yervoy (ipilimumab) in patients suffering from advanced melanoma. The candidate is also being developed in a phase II monotherapy study in patients suffering from ovarian cancer.
Incyte’s oncology portfolio consists of Jakafi, which is approved in the US and EU for the treatment of myelofibrosis (MFGLQ). Jakafi is also being studied for the treatment of polycythemia vera, essential thrombocythemia, solid/other hematologic tumors and pancreatic cancer.
Apart from INCB024360, Incyte’s pipeline consists of INCB28060 (solid tumors) and INCB39110 (myelofibrosis, rheumatoid arthritis, psoriasis) among others.
Incyte, a biopharma company, currently carries a Zacks Rank #3 (Hold). Other biopharma stocks such as Jazz Pharmaceuticals Public Limited Company (JAZZ) and Santarus Inc. (SNTS) currently look better positioned carrying a Zacks Rank #1 (Strong Buy).
More From Zacks.com